Thursday, October 22, 2020
Home Tags Rucaparib

Tag: rucaparib

With Rucaparib Approval, Prostate Cancer Joins the Precision Oncology Era

In an unusual move, the US Food & Drug Administration on May 15, 2020, granted accelerated approval to Clovis Oncology for the oral PARP...

Pivotal rucaparib phase 3 mCRPC data published

The pivotal findings from the phase 3 TRITON2 trial, which led to the FDA approval of rucaparib (Rubraca) in BRCA-positive metastatic castration-resistant prostate cancer...

NCCN Adds Rucaparib to Prostate Cancer Guidelines

Patrick J. Mahaffy The National Comprehensive Cancer Network has updated its Clinical Practice Guidelines in Oncology for Prostate...

Rucaparib Sparks Major Change in the Prostate Cancer Space

Until the recent FDA approval of rucaparib (Rubraca) for BRCA-mutant metastatic castration-resistant prostate cancer (mCRPC), this patient population had no biomarker-driven therapies. But now...

Rucaparib Induces Responses in Men With Metastatic Castration-Resistant Prostate Cancer

Although limited radiographic or prostate-specific antigen (PSA) responses were observed with rucaparib (Rubraca) as treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who...

Clovis Oncology to Highlight Expanded Data from Rubraca® (rucaparib) TRITON and...

Sept. 12, 2019 08:00 UTC BOULDER, Colo.--(BUSINESS WIRE)-- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that three posters highlighting studies from the Rubraca® (rucaparib) clinical...
20,764FansLike
2,389FollowersFollow
16,600SubscribersSubscribe

EDITOR PICKS